TY - JOUR T1 - ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus JF - Evidence Based Medicine JO - Evid Based Med SP - 218 LP - 218 DO - 10.1136/ebmed-2014-110048 VL - 19 IS - 6 AU - Ziv Harel AU - Samuel A Silver Y1 - 2014/12/01 UR - http://ebm.bmj.com/content/19/6/218.abstract N2 - Commentary on: Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773–85.OpenUrlCrossRefPubMedWeb of Science Renin-angiotensin system blockade has been proven to reduce mortality and morbidity in populations at high risk for cardiovascular events. This extends to the patients with diabetes mellitus, where evidence-based guidelines recommend first -line treatment with ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in patients with hypertension and/or proteinuria.1 However, few studies have directly compared ACEIs to ARBs in a randomised-controlled trial (RCT) design. Since ACEIs and ARBs antagonise the renin-angiotensin system through different mechanisms, it is possible that their effects on mortality and cardiovascular outcomes may not be identical. This was a meta-analysis of RCTs that compared different ACEI and ARB regimens in patients with diabetes … ER -